CD Biosynsis offers specialized Mammalian Cells CRISPR Interference (CRISPRi) Gene Repression Services, providing tunable and reversible control over target gene expression in hosts like CHO (Chinese Hamster Ovary) cells and HEK293 cells. CRISPRi utilizes a deactivated Cas9 (dCas9) and a guide RNA (gRNA) to effectively repress gene transcription without permanently altering the genomic DNA sequence. This is a powerful technique for fine-tuning metabolic pathways (e.g., controlling carbon flux), balancing the expression of host factors (e.g., chaperones), and managing the expression of genes whose complete knockout would be lethal. Our services are essential for predictable and efficient optimization of mammalian cell line performance, allowing for rapid screening of optimal expression levels to maximize specific productivity (Qp), reduce byproduct accumulation, and enhance cell viability in bioreactor cultures.
Get a QuoteOptimizing mammalian cell metabolism and anti-apoptosis pathways requires subtle, non-lethal adjustments to native enzyme activity. Full gene knockouts are often too disruptive, leading to unpredictable or detrimental outcomes. Our CRISPRi platform is specifically optimized for mammalian hosts, employing dCas9 efficiently delivered (via lentivirus or stable plasmid) and targeted to promoter regions or initial coding sequences. This enables reliable gene knockdown (partial repression), which is crucial for safely balancing the energy supply in metabolic pathways, reducing toxic byproduct formation (lactate), and managing the host's stress response. This capability accelerates the optimization phase by allowing for rapid, non-permanent testing of various expression levels.
Rational gRNA Design
Computational design of single guide RNAs (gRNAs) targeting promoter regions or the initial coding sequence to achieve maximal transcriptional repression efficiency and allelic coverage in mammalian hosts.
Tunable Repression Libraries
High-diversity gRNA library generation to screen multiple repression levels per target gene, allowing rapid optimization of metabolic flux for enhanced productivity (Qp).
Multiplex Repression
Strategies to simultaneously repress multiple genes (e.g., LDHA and specific chaperones) using a single delivery system to achieve complex, balanced host traits.
dCas9 Stable Integration
Stable integration of the dCas9 (deactivated Cas9) cassette via lentivirus or plasmid into the host genome to create a constitutive, repressible platform, ready for gRNA introduction.
Inducible Repression Systems
Development of systems (e.g., Tet-On/Off) to control dCas9 or gRNA expression, enabling temporal regulation of target gene repression for specific culture phases.
NLS-dCas9 Delivery
Use of dCas9 equipped with a Nuclear Localization Signal (NLS) tag to ensure efficient transport and rapid targeting to the genomic DNA in the nucleus.
Lactate Metabolism Control
Partial repression of glycolytic enzymes or lactate dehydrogenase (LDHA) to safely shift glucose metabolism towards the TCA cycle, reducing toxic lactate byproduct formation.
ER Stress and Folding Tuning
Tunable repression of specific folding chaperones (e.g., BiP) to manage ER stress and prevent inclusion body formation, optimizing the production of complex proteins.
Apoptosis Pathway Management
Partial repression of pro-apoptotic genes (e.g., Bax, Bak) to safely extend cell viability under industrial fed-batch stress, boosting final volumetric titer.
A systematic process from target identification to validated, repressible cell line delivery.
1. Target Identification & Design
2. CRISPRi System Construction & Delivery
3. Clonal Isolation and Screening
4. Verification and Delivery
Identify metabolic, folding, or viability targets for repression. Design gRNA(s) for the promoter or initial coding sequence.
Construct the dCas9 stable integration cassette (if required) and gRNA expression vectors (multiplex or library).
Define screening assays to measure repression efficiency and phenotypic improvement.
Deliver the dCas9 cassette (if stable) and the gRNA vector into the mammalian host cell line.
Culture and select for stable clones using antibiotic markers or FACS sorting.
Confirm dCas9 integration and initial gRNA expression in the bulk population.
Verify gene repression level via qPCR and Western Blot to confirm dCas9 efficacy and protein knockdown.
Phenotypic validation of the resulting trait (e.g., extended viability, higher soluble yield) over multiple passages.
Delivery of the verified, repressible Master Cell Bank (MCB) and full data report.
Tunable Metabolic Control
CRISPRi provides graded repression (knockdown), allowing for safe, subtle tuning of metabolic flux (e.g., lactate reduction) without lethal full gene knockouts.
Non-Permanent Optimization
The repression is reversible (by removing the gRNA), ideal for rapidly testing and optimizing expression strategies and host factor levels (e.g., ER chaperones).
Apoptosis Management
Allows for safe, partial repression of pro-apoptotic genes, significantly extending the cell culture's productive lifespan under industrial stress, boosting final titer.
Accelerated Screening
The ability to screen libraries of repression levels (varying gRNA designs) accelerates the DBTL cycle, quickly identifying the optimal balance point for host performance.
1. Why choose CRISPRi over gene knockout for metabolic tuning?
Metabolic pathways rely on essential genes (e.g., in glycolysis). Knockout would be lethal. CRISPRi allows for partial, safe repression (knockdown) to find the optimal metabolic balance without risking cell death.
2. How does CRISPRi reduce lactate production?
It can partially repress the gene for lactate dehydrogenase (LDHA), which converts pyruvate to lactate. This subtle reduction shifts the metabolic flux away from lactate production toward the efficient TCA cycle, reducing toxic byproduct accumulation.
3. How is the dCas9 system delivered for stable cell line creation?
For stable clonal lines, the dCas9 expression cassette (often containing an NLS tag) is typically integrated into a genomic locus via lentivirus or plasmid transfection/selection to ensure constitutive expression in all generations.
4. Can you use CRISPRi to manage protein folding stress?
Yes. By targeting and partially repressing specific folding chaperones (e.g., BiP) or PDI, we can subtly manage ER stress, preventing the over-accumulation of misfolded proteins and maximizing the yield of soluble, active product.
5. How is the repression level verified?
Repression efficiency is verified using quantitative methods such as quantitative PCR (qPCR) to measure the reduction in target gene mRNA levels, and Western Blot to confirm the corresponding decrease in functional protein levels.
6. What delivery methods are used for the gRNA?
Once the dCas9 is stable, the gRNA is introduced via a separate plasmid (often non-integrating) or lentivirus. This modular system allows for rapid swapping of gRNAs to test different repression targets or levels.
7. What input is required to start a CRISPRi repression project?
We require the specific mammalian host cell line (e.g., CHO-K1) and the accession number or sequence of the target gene(s) you wish to repress (e.g., LDHA, a pro-apoptotic regulator, or a specific chaperone).
8. What is the biggest advantage of CRISPRi for anti-apoptosis engineering?
It allows for safe management of the essential apoptosis pathway. Repressing pro-apoptotic genes (like Bax/Bak) extends viability, but since the repression is partial, the cell retains the essential ability to die under severe distress, preventing accumulation of unhealthy cells.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.